Chronic Primary Immune Thrombocytopenia (ITP)
Conditions
Keywords
ITP, Primary Immune Thrombocytopenia, Autoimmune Disease, Hemorrhagic Disorders, Hematologic Diseases, Blood Coagulation Disorders
Brief summary
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
Interventions
BIOLOGICALKedrion IVIG 10%
(Intravenous) Human Normal Immunoglobulin (IVIg) 10%
Sponsors
Kedrion S.p.A.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female, 18-70 years of age. 2. Patient has signed the ICF. 3. Diagnosis of chronic (\> 12 months duration) ITP as defined by the International Working Group. 4. Mean screening platelet count of \< 30 × 10\^9/L from two qualifying counts measured at least one calendar day apart. The first qualifying count can be from historical data if measured within 7 days prior to screening. The second qualifying count will be measured within 7 days before the first KIg10 infusion. 5. A pre-infusion platelet count of \< 30 × 10\^9/L at the Baseline Visit. 6. Patient is willing to comply with all requirements of the protocol. 7. Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at screening and agree to employ adequate birth control measures during the study. 8. Authorization to access personal health information.
Exclusion criteria
1. Patients incapable of giving informed consent. 2. Patients with secondary ITP (all forms of immune-mediated thrombocytopenia except primary ITP). e.g., lupus erythematosus, rheumatoid arthritis, drug-related ITP, and Human Immunodeficiency Virus (HIV). 3. Patients with Evans Syndrome. 4. Patients known to be infected with hepatitis B virus, hepatitis C virus, or HIV. 5. History of thrombotic events including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, transient ischemic attacks, or myocardial infarction. 6. Patient with a history of hypersensitivity to IVIg, other injectable forms of IVIg, or to any of the excipients. 7. Patient unresponsive previously to IVIg or anti-D Ig treatment. 8. Patient with known Immunoglobulin A (IgA) deficiency and antibodies against IgA. 9. Splenectomy within 4 weeks of the Baseline Visit or planned splenectomy throughout the study period. 10. Participants with known inherited thrombocytopenia. e.g., MYH-9 disorders. 11. Participants with myelodysplastic syndrome (MDS). 12. Administration of IVIg, anti-D immunoglobulin, Mercaptopurine, Vinca alkaloid, or platelet enhancing drugs (including thrombopoietin receptor agonists \[TPO-RA\], immunosuppressive, or other immunomodulatory drugs) within 3 weeks of the Baseline Visit, except for: 1. patients on a stable dose of TPO-RA within 4 weeks of the Baseline Visit 2. patients on a stable dose of Mycophenolate Mofetil within 3 months of the Baseline Visit 3. patients on stable dose of Danazol within 3 months of the Baseline Visit 4. long-term corticosteroid therapy for ITP, when the dose had been stable within 3 weeks of the Baseline Visit and no dosage change was planned until the EOS Visit 5. long-term azathioprine, cyclophosphamide, or attenuated androgen therapy when the dose had been stable within 3 months of the Baseline Visit, and no dosage change was planned until after study completion. Treatment with any other products licensed for primary chronic ITP is also exclusive. An appropriate wash-out period must be determined in case of patients who might be eligible for treatment with IVIg. 13. Received any blood, blood product, or blood derivative within 1 month of the Baseline Visit. 14. Received rituximab within 6 months of the Baseline Visit. 15. Had a platelet transfusion or receipt of blood products containing platelets within 7 days of Visit 1 (Day 1). 16. Received recombinant activated factor VII within 7 days of the Baseline Visit. 17. Had therapy with live attenuated virus vaccines within 3 months of the Baseline Visit. 18. Use of loop diuretics within 1 week of the Baseline Visit. 19. Patients at high risk of thrombotic events. 20. Uncontrolled hypertension \[i.e., diastolic blood pressure \>100 mmHg and/or systolic blood pressure \>160 mmHg\]. If a single measure exceeds this limit, a triple repeat measurement may be performed and the average of the three measurements used. 21. Congestive heart failure as per New York Heart Association III/IV, cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g., atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity. 22. Patients with significant protein losing enteropathy, nephrotic syndrome, or lymphangiectasia. 23. Patients with hyperproteinemia, increased serum viscosity, and/or hyponatremia. 24. Severe liver or kidney disease (normal reference ranges of laboratory doing the analysis): 1. alanine aminotransferase (ALT) or aspartate amino transferase (AST) 2.5x \> upper limit of normal (ULN) 2. creatinine \> 120 μmol/L 3. blood urea nitrogen (BUN) \> 2.5x ULN 25. Signs of severe anemia: Hemoglobin of less than 7 g/dL, hemodynamically unstable due to active bleeding, and/or when evidence of end-organ ischemia secondary to severe anemia is present. 26. Body mass index \> 40 kg/m2 or an IVIg dose that puts the patient at risk of fluid overload. 27. History of a malignant disease within 3 years of the Baseline Visit other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin. 28. Patient has participated in an interventional, investigational clinical study within 30 days of the Baseline Visit or within 5 half-lives of the investigational medicinal product (IMP) under investigation. 29. Any condition that the Investigator believes is likely to interfere with evaluation of the IMP or with satisfactory conduct of the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of subjects with response (R) | Treatment to day 14 | Assess the responder rate by measuring the platelet count increase according to the Response (R) definition and the absence of bleeding during the evaluation period |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number and rate of subjects with complete response (CR) | Treatment to day 14 | Assess the clinical response rate by measuring the platelet count increase and absence of bleeding according to the Complete Response (CR) |
| Time to platelet count response | Treatment to day 14 | Assess the time from starting treatment to time of achievement of CR or R |
| Duration of response | 14 days after treatment to end of study | Measured from achievement of CR or R to loss of CR or R |
| Regression of hemorrhages | Day 1 (Visit 1) to Day 30 (End of Study Visit) | Time to stop bleedings |
| Platelet count assessment | Day 1 (Visit 1) to Day 30 (End of Study Visit) | Assess the maximum platelet count and time to achieve the maximum platelet count |
| Assess safety and tolerability | Day 1 (Visit 1) to Day 30 (End of Study Visit) | Number and percentage of all adverse events (AEs) and serious adverse events (SAEs) |
Countries
Czechia, Germany, Italy, Romania, Serbia, Spain, Turkey (Türkiye), United States
Contacts
CONTACTAnna Lotti Suffredini
CONTACTLinda Karpiak
STUDY_DIRECTORMirella Calcinai, MD
Kedrion S.p.A.
Outcome results
None listed